Evidence map›Paper›PMID 26396071›Full record

ArticleBMC health services research2015

Making sense of a new technology in clinical practice: a qualitative study of patient and physician perspectives.

Regitze A S Pals, Ulla M Hansen, Clea B Johansen, Christian S Hansen, Marit E Jørgensen, Jesper Fleischer, Ingrid Willaing

Abstract read
In one paragraph

Article in BMC health services research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Regitze A S PalsHealth Promotion Research, Steno Diabetes Center A/S, Gentofte, Denmark. riap@steno.dk.
Ulla M HansenHealth Promotion Research, Steno Diabetes Center A/S, Gentofte, Denmark. uamh@steno.dk.
Clea B JohansenHealth Promotion Research, Steno Diabetes Center A/S, Gentofte, Denmark. cbuj@steno.dk.
Christian S HansenClinical Epidemiology Research, Steno Diabetes Center A/S, Gentofte, Denmark. csvh@steno.dk.
Marit E JørgensenClinical Epidemiology Research, Steno Diabetes Center A/S, Gentofte, Denmark. maej@steno.dk.
Jesper FleischerMedical Research Laboratories, Clinical Institute of Medicine, Aarhus University, Aarhus, Denmark. jesper.fleischer@ki.au.dk.
Ingrid WillaingHealth Promotion Research, Steno Diabetes Center A/S, Gentofte, Denmark. iwtp@steno.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of new technologies for risk assessment available in health care is increasing. These technologies are intended to contribute to both improved care practices and improved patient outcomes. To do so however, there is a need to study how new technologies are understood and interpreted by users in clinical practice. The objective of this study was to explore patient and physician perspectives on the usefulness of a new technology to detect Cardiovascular Autonomic Neuropathy (CAN) in a specialist diabetes clinic. The technology is a handheld device that measures resting heart rate and conducts three cardiac autonomic reflex tests to evaluate heart rate variability.

methodsThe study relied on three sources of data: observations of medical consultations where results of the CAN test were reported (n = 8); interviews with patients who had received the CAN test (n = 19); and interviews with physicians who reported results of the CAN test (n = 9). Data were collected at the specialist diabetes clinic between November 2013 and January 2014. Data were analysed using the concept of technological frames which is used to assess how physicians and patients understand and interpret the new technology.

resultsPhysicians generally found it difficult to communicate test results to patients in terms that patients could understand and to translate results into meaningful implications for the treatment of patients. Results of the study indicate that patients did not recall having done the CAN test nor recall receiving the results. Furthermore, patients were generally unsure about the purpose of the CAN test and the implications of the results. DISCUSSION: Involving patients and physicians is essential when a new technology is introduced in clinical practice. This particularly includes the interpretation and communication processes related to its use.

conclusionsThe integration of a new risk assessment technology into clinical practice can be accompanied by several challenges. It is suggested that more information about the CAN test be provided to patients and that a dialogue-based approach be used when communicating test results to patients in order to best support the use of the technology in clinical practice.

Indexed as

Biomedical TechnologyGeneral PracticeHealth Knowledge, Attitudes, PracticeAdultAgedCommunicationDenmarkFemaleHumansInterviews as TopicMaleMiddle AgedObservationPhysiciansQualitative ResearchSpecialization

Identifiers

PMID26396071
PMCPMC4580358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.